Quick Answer
Praxis Precision Medicines, Inc. reported Operating Income Loss of -$326.20 million for the year ending 2025.
- Praxis Precision Medicines, Inc. showed a decrease of -63.0% in Operating Income Loss from 2024 to 2025.
- This data is from Praxis Precision Medicines, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$10.65 million | Q1 2020: -$8.47 million | Q2 2020: -$11.57 million | Q3 2020: -$16.22 million | Q1 2021: -$27.42 million | Q2 2021: -$36.48 million | Q3 2021: -$44.77 million | Q1 2022: -$68.85 million | Q2 2022: -$60.39 million | Q3 2022: -$44.29 million | Q1 2023: -$38.09 million | Q2 2023: -$34.96 million | Q3 2023: -$25.52 million | Q1 2024: -$41.89 million | Q2 2024: -$37.49 million | Q3 2024: -$56.84 million | Q1 2025: -$74.73 million | Q2 2025: -$76.07 million | Q3 2025: -$78.36 million.
- Over the full 7 years of available data (2019 to 2025), Praxis Precision Medicines, Inc.'s Operating Income Loss has declined by 811.4%.
- Historical annual values: Fiscal year 2025: -$326.20 million | Fiscal year 2024: -$200.17 million | Fiscal year 2023: -$126.37 million | Fiscal year 2022: -$214.99 million | Fiscal year 2021: -$167.33 million | Fiscal year 2020: -$61.97 million | Fiscal year 2019: -$35.79 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: